# Jim Robinson

> Jim Robinson is the president and chief executive officer of A2 Biotherapeutics, where he is guiding a clinical-stage company built around Tmod, a two-receptor system designed to help engineered T cells distinguish tumor cells from normal tissue. A DePaul marketing graduate who began as a Schering-Plough sales representative in 1992, Robinson spent more than 12 years at Astellas, became president and COO of Alkermes, led Urovant Sciences through its first product approval and launch, and joined A2 Bio in April 2024. His career is defined less by laboratory invention than by the operational work of turning complex science into functioning teams, funded programs and products.

- **Role:** President and Chief Executive Officer at A2 Biotherapeutics
- **Organizations:** A2 Biotherapeutics, Urovant Sciences, Paragon Biosciences, Alkermes, Astellas Pharma, Schering-Plough Pharmaceuticals, Eledon Pharmaceuticals, UroGen Pharma, Petauri Health
- **Nationality:** American
- **Education:** Bachelor of Science in Marketing, DePaul University
- **Known for:** Guided Urovant Sciences through FDA approval and launch of its first product and through its acquisition by Sumitovant Biopharma., Led Astellas Americas with responsibility for approximately $4 billion in revenue., Led Alkermes operations associated with more than $1 billion in annual revenue.

## Career timeline

- **1992** — Began his biopharmaceutical career at Schering-Plough after earning a BS in Marketing from DePaul University.
- **c. 2005-2018** — Spent more than 12 years at Astellas Pharma and ultimately served as President of the Americas, with responsibility for approximately $4 billion in revenue.
- **2018-2019** — Served as President and Chief Operating Officer of Alkermes, leading operations associated with more than $1 billion in annual revenue.
- **2019-2020** — Served as President and Chief Operating Officer of Paragon Biosciences.
- **2020-2023** — Served as President and CEO of Urovant Sciences, leading its first FDA approval, product launch and acquisition by Sumitovant Biopharma.
- **2023** — Received PM360's Trailblazer Award for Life Sciences Manufacturer CEO of the Year and joined the boards of Eledon Pharmaceuticals and Petauri Health.
- **2024** — Joined A2 Biotherapeutics as President and CEO and a member of its board, effective April 1.
- **2025** — Led A2 Bio as it closed an $80 million Series C financing to advance three clinical development programs and its Tmod pipeline.
- **2026** — Led A2 Bio through an IND clearance, first-patient dosing and Fast Track designation for A2B543, alongside clinical updates from EVEREST-2 and DENALI-1.

## Achievements

- Guided Urovant Sciences through FDA approval and launch of its first product and through its acquisition by Sumitovant Biopharma.
- Led Astellas Americas with responsibility for approximately $4 billion in revenue.
- Led Alkermes operations associated with more than $1 billion in annual revenue.
- Received the 2023 PM360 Trailblazer Award for CEO of the Year in the Life Sciences Manufacturer category.
- As A2 Bio CEO, closed an $80 million Series C financing to support three clinical programs and the Tmod pipeline.
- Has served on the boards of A2 Biotherapeutics, Eledon Pharmaceuticals, UroGen Pharma and Petauri Health, with prior directorships at Neos Therapeutics and Applied Genetic Technologies Corporation.

## Latest updates

- **2026-09** — A2 Bio reported early DENALI-1 data from 10 treated patients, including a reported complete response in metastatic anal cancer and a confirmed partial response in head and neck cancer.
- **2026-05** — A2 Bio presented updated EVEREST-2 safety and efficacy data, including follow-up on a complete response in a non-small cell lung cancer patient.
- **2026-04** — The FDA granted Fast Track designation to A2B543, A2 Bio's logic-gated autologous CAR-T candidate with a membrane-tethered IL-12 booster.
- **2026-02** — A2 Bio dosed the first patient in the EVEREST-2 study with A2B543.
- **2026-01** — The FDA cleared A2 Bio's IND for A2B543.
- **2025-01** — A2 Bio closed an $80 million Series C financing backed by investors including The Column Group and Samsara BioCapital.

## Links

- Website: https://www.a2bio.com
- LinkedIn: https://www.linkedin.com/in/jim-robinson-69a7873a

---

Profile page: https://yespress.io/jim-robinson
Published by YesPress — https://yespress.io
Last updated: 2026-09-27